Intranasal vaccination of calves with Mannheimia haemolytica chimeric protein containing the major surface epitope of outer membrane lipoprotein PlpE, the neutralizing epitope of leukotoxin, and cholera toxin subunit B.
This study was done to determine if intranasal vaccination of weaned beef calves with a chimeric protein containing the immunodominant surface epitope of Mannheimia haemolytica PlpE (R2) and the neutralizing epitope of leukotoxin (NLKT) covalently linked to truncated cholera toxin (CT) subunit B (CTB) could stimulate secretory and systemic antibodies against M. haemolytica while enhancing resistance of cattle against M. haemolytica intrabronchial challenge. Sixteen weaned beef calves were intranasally vaccinated with CTB-R2-NLKT chimeric (SAC102) or with R2-NLKT-R2-NLKT chimeric (SAC89) protein with or without native CT on days 0 and 14 and were challenged intrabronchially on day 28. In vitro, SAC102 bound the CT receptor molecule, GM(1)-ganglioside. Mean IgA antibodies to M. haemolytica whole cells (WC) and to LKT were high on day 0. A small, yet significant increase (p<0.05) was found in mean nasal antibodies to M. haemolytica WC for the SAC89+CT and SAC102 vaccinates after the second vaccination. SAC102 stimulated significant (p<0.05) mean serum antibody responses to all three antigens by day 28. Following challenge, mean antibodies to WC and LKT significantly increased (p<0.05) for the SAC102, SAC89 and SAC89+CT groups with the mean antibody responses to rPlpE stimulated by SAC102 vaccination being significantly higher (p<0.05) than for the other vaccinated and control groups. On day 1 after challenge, mean clinical score for the control group was significantly higher (p<0.05) than for the SAC102 and SAC89+CT vaccinates, and by day 2 after challenge, clinical score for the control group was significantly higher (p<0.05) than for all three chimeric vaccinated groups. Therefore, intranasal vaccination with CTB-R2-NLKT (SAC102) and R2-NLKT-R2-NLKT (SAC89) chimeric proteins enhanced resistance against intrabronchial challenge with the bacterium as well as stimulating antibody responses to M. haemolytica antigens.
Ayalew
S
S
Department of Veterinary Pathobiology, Center for Veterinary Health Sciences, Oklahoma State University, 250 McElroy Hall, Stillwater, OK 74078-2007, USA.
Step
D L
DL
Montelongo
M
M
Confer
A W
AW
D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D057134:Antibodies, Neutralizing / Q000096:biosynthesis; D001425:Bacterial Outer Membrane Proteins / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology*; D001428:Bacterial Vaccines / Q000008:administration & dosage* / Q000235:genetics; D001483:Base Sequence; D002417:Cattle; D002772:Cholera Toxin / Q000008:administration & dosage*; D017931:DNA Primers / Q000235:genetics; D004269:DNA, Bacterial / Q000235:genetics; D000939:Epitopes / Q000008:administration & dosage / Q000235:genetics; D005098:Exotoxins / Q000008:administration & dosage* / Q000276:immunology*; D005677:G(M1) Ganglioside / Q000378:metabolism; D008074:Lipoproteins / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology*; D016978:Mannheimia haemolytica / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D012766:Pasteurellosis, Pneumonic / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics
D000907:Antibodies, Bacterial; D057134:Antibodies, Neutralizing; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D017931:DNA Primers; D004269:DNA, Bacterial; D000939:Epitopes; D005098:Exotoxins; D008074:Lipoproteins; C116100:PlpE protein, Pasteurella haemolytica; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic; C018579:leukotoxin; D005677:G(M1) Ganglioside; D002772:Cholera Toxin